ClinicalTrials.gg
RecruitingNCT05717608ERIEUpdated Feb 8, 2023

Effect Dietary Fructose on Fructose Kinetics in Type 2 Diabetes

An interventional study of high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects in Type 2 Diabetes, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Planned enrollment
4th of 10
40 · median 36
Started
2023
with 3 others
No phase
9 of 12
1 open now
Registered
8th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 with no phase, and was the 8th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

Determine the kinetics of fructose metabolism and its role as a metabolic substrate following a high (100gr/day) vs low fructose diet (\<30 gram fructose intake per day isocaloric correction with dextrose) in type 2 diabetic subjects of SAS or Caucasian ethnicity.

Read the detailed description

The prevalence and accompanying morbidity and mortality of obesity and type 2 diabetes (T2D) is increasing on a global scale. Unfortunately the underlying (patho)physiological mechanisms are only partially understood. A key step in the development of negative health effects of metabolic disease might be via dietary fructose metabolism and its accompanying aberrant metabolite production, in which our gut microbiota plays a crucial role.

By bypassing the normal glucose metabolism pathway, fructose plays a role in the development of metabolic disease such as diabetes en fatty liver disease. The mechanism of this effect is unclear and possibly plays in the observation of ethnic specific metabolic risk factors. That is, subjects of different ethnicties (for instance South-Asian Surinamese (SAS)) have a higher risk and worse trajectory of metabolic diseases than Caucasians. Since gut microbiota is altered between these two ethnicities, we hypothesize that aberreant fructose catabolism in patients of SAS descent results in production of specific (gut microbiota derived) metabolites such as ethanol. In this study, fructose metabolism will thus be studied in patients of SAS and Caucasian Dutch descent. To this end the investigators will examine (13C stable isotope based) fructose fluxes before and after randomizing subjects into a four-week high- or low fructose diet. This study aims to elucidate the physiological and microbial catabolism of fructose and possible differences between these two ethnicities.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40 T2D patients (20 Caucasian and 20 SAS)
  • 40-70 years old
  • Male-female
  • 25-35 kg/m2
  • Stable anti diabetic drugs for 3 months (metformin is obligatory)
  • Stable medication use past 3 months
  • Able to give

Exclusion criteria

Exclusion Criteria:

    • Proton-pump inhibitor usage (known to effect gut microbiota)
  • GLP1, SGLT2i or insulin use (known to effect gut microbiota)
  • Antibiotic for the past 3 months (known to effect gut microbiota)
  • Probiotic or symbiotic usage (known to effect gut microbiota)
  • Pregnant women
  • Chronic illness (including a known history of heart failure, renal failure ( \<30 ml/min), pulmonary disease, gastrointestinal disorders, or hematologic diseases), or other inflammatory diseases
  • Active infection
  • Previous intestinal (e.g., bowel resection/reconstruction) surgery
  • Smoking (due to its influence on gut microbiome)
  • Vegetarian diet (since they have different microbiota)
  • >6 alcohol units per day or >14 alcohol units per week
  • Active
  • >9% (75mmol/mol)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    high fructose in caucasian dutch type 2 diabetes subjects

    high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.

    Other: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects

  • Placebo comparator
    low fructose in caucasian dutch type 2 diabetes subjects

    low fructose diet (\<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.

    Other: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects

  • Active comparator
    high fructose in surinamese asian type 2 diabetes

    high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of SAS ethnicity.

    Other: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects

  • Placebo comparator
    low fructose in surinamese asian type 2 diabetes

    low fructose diet (\<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of SAS ethnicity.

    Other: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects

Interventions

  • Otherhigh vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects

    oral ingestion of food supplement for 4 weeks

06

What researchers measure

Primary outcomes

  1. fructose on glucose metabolism

    to correlate changes in oral fructose handling (measured by a fructose challenge test (AUC) with 13C6-labeled fructose in relation to metabolic effects on HOMA-IR and continuous glucose monitoring (Freestyle libre MAGE) at baseline and after 4 weeks of dietary intervention.

    Time frame: 4 weeks

Secondary outcomes

  1. changes in microbiota composition

    correlate with changes in oral/fecal microbiota composition (diversity and strain)

    Time frame: 4 weeks

  2. changes in (postprandial )plasma metabolites

    effects of the diet on body composition (measured via bio impedance analysis). We will also collects 24h feces and urine before each study visit to determine correlate with changes in (postprandial) untargeted plasma metabolites including endogenous ethanol

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — not allowed due to dutch GDPR regulations

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2023; primary completion for Dec 2025, 34 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 34 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2023
First posted
Feb 8, 2023
StartEst.
Feb 5, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Apr 30, 2026
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05717608
Responsible party
Max Nieuwdorp (professor, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Feb 8, 2023
Start date
Feb 5, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Feb 8, 2023

Study contacts

cengiz callender, MD
Contact
c.callender@amsterdamumc.nl
0031 20 5669111
max nieuwdorp, MD PhD
Contact
m.nieuwdorp@amsterdamumc.nl
0031 20 5669111
max nieuwdorp
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion